• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CBFO Rona Jeffrey A sold $2,185 worth of shares (3,902 units at $0.56), decreasing direct ownership by 5% to 67,973 units (SEC Form 4)

    2/28/25 4:15:08 PM ET
    $OVID
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OVID alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Rona Jeffrey A

    (Last) (First) (Middle)
    C/O OVID THERAPEUTICS INC.
    441 NINTH AVENUE

    (Street)
    NEW YORK NY 10001

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Ovid Therapeutics Inc. [ OVID ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CBFO
    3. Date of Earliest Transaction (Month/Day/Year)
    02/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/26/2025 S 3,902(1) D $0.56 67,973 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
    /s/ Jason Minio, Attorney-in-Fact 02/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OVID alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OVID

    DatePrice TargetRatingAnalyst
    6/18/2024Outperform → Perform
    Oppenheimer
    4/30/2024$9.00Buy
    B. Riley Securities
    4/29/2024$9.00Buy
    H.C. Wainwright
    4/5/2024$8.00Outperform
    Wedbush
    12/21/2023$11.00Buy
    BTIG Research
    10/13/2023$8.00Outperform
    Oppenheimer
    8/25/2021$4.50 → $4.00Neutral
    Citigroup
    More analyst ratings

    $OVID
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

      NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on Monday, April 7, 2025, at 8:45 AM. ET. A live webcast of the Needham Virtual Healthcare Conference presentation can be accessed through the Events & Presentations section of the company's website at  investors.ovidrx.com. An archived replay of the webcast will be available on the Company's website following the live presentation for approximately 30 da

      4/2/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

      Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinicTopline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, safety, and tolerabilityOV350, Ovid's first program in its KCC2 direct activator library, initiated a first-in-human study in Q1 2025Cash, cash equivalents and marketable securities of $53.1 million as of December 31, 2024, are expected to support operations and development programs into the second half of

      3/11/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Leadership Updates

    Live Leadership Updates

    See more
    • Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

      NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors. "Stelios is a pioneering force in biotechnology. His vision and strategic acumen have shaped the landscape of our industry—building companies, financing breakthroughs, and enabling transformative medicines. We are honored to welcome him to our Board at a defining moment for Ovid," said Jeremy Levin, D.Phil, MB BChir, Chairman and CEO of Ovid Therapeutics. "With our advancing pipeline, including

      3/3/25 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development Officer

      NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the appointment of Amanda Banks, M.D., as Chief Development Officer. Dr. Banks will oversee Ovid's clinical development, medical, and regulatory affairs functions as well as drive corporate development strategy and execution in partnership with the Company's leadership team. Dr. Banks brings to Ovid broad and deep experience in neurology, clinical strategy, and business development. Her strategic acumen will serve Ovid at an important juncture for the Company as it determ

      8/8/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists

      Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid's Scientific Advisory Board (SAB)Neuroscientists Dr. Jamie Maguire of Tufts University and Dr. Jeff Noebels of Baylor College of Medicine, appointed to the SAB to contribute expertise in neurophysiology, hyperexcitability and network effectsThe SAB will advise on the potential application of Ovid's compounds to broader disorders in which they may offer therapeutic promise, including brain conditions caused by hyperexcitability, neurovascular and neuro-inflammatory d

      7/23/24 8:00:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 6:01:44 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ovid Therapeutics Inc.

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      11/14/24 4:39:42 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Ovid Therapeutics Inc. (Amendment)

      SC 13G/A - Ovid Therapeutics Inc. (0001636651) (Subject)

      2/14/24 4:15:31 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Papadopoulos Stelios

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:44:34 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Papadopoulos Stelios claimed ownership of 200,000 shares (SEC Form 3)

      3 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/4/25 4:42:41 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CBFO Rona Jeffrey A sold $2,185 worth of shares (3,902 units at $0.56), decreasing direct ownership by 5% to 67,973 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      2/28/25 4:15:08 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    SEC Filings

    See more
    • SEC Form 8-K filed by Ovid Therapeutics Inc.

      8-K - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:14:40 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Ovid Therapeutics Inc.

      PRE 14A - Ovid Therapeutics Inc. (0001636651) (Filer)

      5/2/25 4:09:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-K/A filed by Ovid Therapeutics Inc.

      10-K/A - Ovid Therapeutics Inc. (0001636651) (Filer)

      4/30/25 4:06:12 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and COO Alexander Margaret A. bought $4,971 worth of shares (6,810 units at $0.73), increasing direct ownership by 24% to 34,935 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      1/29/25 9:18:08 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Levin Jeremy M bought $50,364 worth of shares (18,248 units at $2.76), increasing direct ownership by 0.51% to 3,616,715 units (SEC Form 4)

      4 - Ovid Therapeutics Inc. (0001636651) (Issuer)

      3/20/24 5:22:00 PM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OVID
    Financials

    Live finance-specific insights

    See more
    • Ligand Reports Second Quarter 2024 Financial Results

      Conference call at 4:30 p.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and six months ended June 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss this announcement and answer questions. "We had a strong quarter and are on track to meet the long-term growth objectives we outlined in December," said Todd Davis, CEO of Ligand. "We added four new commercial-stage programs in the first half of this year, including QARZIBA®, an orphan oncology product we acquired following the APEIRON Biologics transacti

      8/6/24 4:01:00 PM ET
      $AGEN
      $AMGN
      $CASI
      $LGND
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $OVID
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ovid Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Ovid Therapeutics from Outperform to Perform

      6/18/24 7:38:14 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Ovid Therapeutics with a new price target

      B. Riley Securities initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/30/24 8:03:00 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Ovid Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Ovid Therapeutics with a rating of Buy and set a new price target of $9.00

      4/29/24 7:56:55 AM ET
      $OVID
      Biotechnology: Pharmaceutical Preparations
      Health Care